High Background Uptake on MBINCT02979301
Impact of Low-dose Tamoxifen on BPU
A study testing Tamoxifen in people with High Background Uptake on MBI, run by Mayo Clinic at 1 site in United States.
Trial summary
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Read more about this study
- Who is it for?
- Ages 40 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- High Background Uptake on MBI
- What is being tested?
- Tamoxifen
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2017to 1 Nov 2018
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Inclusion Criteria:The following are requirements for entry into the study:
- Female, age 40 or older at the time of enrollment
- Most recent MBI examination, performed within 3 years of enrollment, showed moderate or marked background parenchymal uptake
- Mammogram performed within 12 months prior to enrollment that is available for comparison
- Willing and able to return for MBI following 30 days of low-dose tamoxifen
- If able to become pregnant
- Negative pregnancy test within 48 hours prior to study MBI exam(s)
- Agrees to avoid pregnancy during the study and for at least 2 months after study participation ends, by abstinence, barrier method, or nonhormonal contraception.
- Understands and signs the consent form -
Exclusion Criteria:Subjects will be excluded if any of the following characteristics are present:
- Evidence of suspected breast disease as defined by positive findings or recommendation for short-interval follow-up on most recent breast imaging (including mammography, MBI, MRI, ultrasound, etc.) not yet resolved prior to enrollment 2) Breast biopsy or breast surgery performed 6 months prior to enrollment 3) Bilateral breast implants or status post-bilateral prophylactic mastectomy 4) Pregnant or lactating 5) Current or recent use (within 6 months prior to enrollment) of any of the following drugs:
- Systemic hormonal therapy (oral or transdermal patch formulations)
- Hormonal contraception (oral, transdermal, implanted, or injected formulations)
- Selective estrogen receptor modulators (tamoxifen, raloxifene, or toremifene)
- Aromatase inhibitors (anastrazole, letrozole, or exemestane)
- GnRH analogs
- Prolactin inhibitors
- Androgens or antiandrogens
- Anticoagulants or "blood thinners" (warfarin, heparin, rivaroxaban and other novel anticoagulants)
- Drugs known to be strong inhibitors of CYP2D6, the major P450 enzyme that metabolizes tamoxifen, including:
- bupropion (Wellbutrin)
- fluoxetine (Prozac)
- paroxetine (Paxil)
- quinidine (Quinidex) 6) Personal history of any type of malignancy, with the exclusion of non-melanoma skin cancer, diagnosed prior to enrollment 7) Personal history or strong family history of blood clots in legs or lungs (also known as deep vein thrombosis or pulmonary embolism) 8) Personal history of transient ischemic attack (TIA) or cerebrovascular accident (CVA) 9) Active proliferative disorders of the endometrium such as atypical hyperplasia, history of active endometriosis, unresected polyps 10) Any type of retinal disorders or severe cataract 11) Current or former smoker 12) Known carrier of BRCA1 or BRCA2 genetic mutation or known DNA repair defect.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen on BPU.
- Conditions
- High Background Uptake on MBI
- Being tested
- Tamoxifen
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TamoxifenDrug
5 mg or 10 mg tamoxifen per day for 30 days.
| Study group | Role | What they receive |
|---|---|---|
| Tamoxifen 5 mg/day | Experimental | Women with high background uptake on MBI take 5 mg tam per day for 30 days. Receives: Drug: Tamoxifen |
| Tamoxifen 10 mg/day | Experimental | Women with high background uptake on MBI take 10 mg tam per day for 30 days. Receives: Drug: Tamoxifen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)
An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2016 (estimated)
- Study start1 Mar 2017
- Primary completion25 Feb 2018
- Study completion1 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for High Background Uptake on MBIStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Carrie Hruska, Mayo Clinic
- Investigators
- Carrie Hruska, PhD R-D, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02979301
- Sponsor's protocol ID
- IRB 16-008736
- Status last verified
- Apr 2019
- First submitted
- 29 Nov 2016
- Last updated
- 16 Jul 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O'Connor MK, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Res. 2019 Mar 8;21(1):38. doi: 10.1186/s13058-019-1120-5.
PubMed 30850011
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging
- ClinicalTrials.gov ID
- NCT02979301
- Acronym / sponsor ID
- IRB 16-008736
- Conditions
- High Background Uptake on MBI
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 1 Mar 2017 (actual)
- Primary completion
- 25 Feb 2018 (actual)
- Study completion
- 1 Nov 2018 (actual)
- First posted
- 1 Dec 2016 (estimated)
- Results
- Posted 16 Jul 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen on BPU.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tamoxifen 5 mg/day | Experimental | Drug: TamoxifenWomen with high background uptake on MBI take 5 mg tam per day for 30 days. |
| Tamoxifen 10 mg/day | Experimental | Drug: TamoxifenWomen with high background uptake on MBI take 10 mg tam per day for 30 days. |
Who may qualify
- Ages
- 40 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tamoxifen5 mg or 10 mg tamoxifen per day for 30 days. | Drug | Tamoxifen 10 mg/day, Tamoxifen 5 mg/day |
Primary outcome
Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)
Time frame: 30 days
An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 30850011Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O'Connor MK, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Res. 2019 Mar 8;21(1):38. doi: 10.1186/s13058-019-1120-5.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carrie Hruska, PhD R-D principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tamoxifen in people with High Background Uptake on MBI, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Jul 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI) (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02979301, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2019.